clinical trial · NCT06001658
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·recruiting·n = 27
Billiary Track CancerGemcitabineCisplatinPembrolizumab
brief summary
The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic responses.
started
Jul 8, 2024
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Dec 3, 2025
official title
Tumor Microenvironment Features of Response to Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol